Nerve hydrodissection is the ultrasound-guided injection of fluid around a peripheral nerve in order to separate it mechanically from adjacent tissue thought to contribute to compression, impaired gliding or perineural adherence, producing a visible plane of fluid around the nerve. The idea is that a nerve which is compressed or adherent to surrounding fascia, tendon or scar can be freed by the fluid itself, independently of any pharmacological effect of what is injected. The most studied application by far is carpal tunnel syndrome (CTS), where the median nerve is separated from the flexor tendons and the flexor retinaculum, but the technique is also used around the ulnar nerve at the elbow, the lateral femoral cutaneous nerve, the sciatic nerve in deep gluteal syndrome and various other entrapments. This page covers the technique, the choice of injectate, and how the evidence stands in sport and exercise medicine (SEM) practice.
How is hydrodissection performed?
Hydrodissection is an ultrasound-dependent procedure and cannot sensibly be performed blind, since the whole point is to see fluid separating the nerve from the structure it is stuck to. The nerve is first scanned along its course to assess for findings supportive of entrapment and to identify a safe procedural target; supportive findings include enlargement or flattening of the nerve, swelling proximal to a constriction, altered fascicular pattern, and reduced mobility on dynamic scanning. A path is planned that keeps the needle away from vessels, using colour Doppler where relevant, and the skin is prepared aseptically. In the carpal tunnel a commonly used approach is in-plane from the ulnar side at the level of the pisiform, passing superficial to the flexor tendons, though radial approaches are also described; the ulnar artery and nerve in Guyon's canal must be positively identified with ultrasound and colour Doppler rather than assumed to be avoided by the choice of approach; a small volume is delivered to lift the median nerve away from the flexor tendons beneath it, and the remainder to separate it from the flexor retinaculum above.
In a commonly used carpal tunnel approach the needle is advanced in-plane from the ulnar side and fluid is delivered above and below the median nerve, separating it from the flexor retinaculum and the underlying tendons.
The technical endpoint is visible separation of the nerve from the intended adjacent surfaces without intraneural spread, rather than an absolute requirement for a complete circumferential halo. Two things should not happen: the needle should never be advanced into the nerve itself, and injection should stop immediately if the patient reports sharp radiating pain or if the fascicles appear to swell. Importantly, the absence of sharp pain does not exclude intraneural placement, particularly where local anaesthetic has been used, so the needle tip position, the injection pressure and the fascicular appearance are all monitored. Volumes and technique vary between protocols and the optimal volume is not established. Choice of injectate is a live question. Normal saline is the simplest and isolates the purely mechanical effect. Five per cent dextrose in water is widely used and has encouraging comparative data in carpal tunnel syndrome, although certainty is limited by small heterogeneous trials, with the additional proposed rationale of an effect on sensory nerve signalling. Local anaesthetic is often added for comfort but limits assessment of the immediate response, may produce a temporary nerve block, and can mask the warning symptoms of intraneural injection; corticosteroid is sometimes included, which brings its own tendon and anti-doping considerations. Aftercare is minimal, with splinting continued where it was already in use and activity modification maintained.
What does the evidence show?
Carpal tunnel syndrome is where the evidence is strongest, and it is promising but of low certainty. Randomised trials have compared perineural dextrose hydrodissection against corticosteroid injection and against control, and network analyses of hydrodissection injectates have consistently ranked dextrose among the more effective options for symptom and functional scores over several months. That said, the trials are mostly small, largely from a small number of centres, heterogeneous in volume and technique, and the comparisons are usually against another injection rather than against a sham procedure, so the contribution of the fluid itself remains less well isolated than it appears. Outside the carpal tunnel the evidence thins quickly: use around the ulnar nerve, lateral femoral cutaneous nerve and sciatic nerve rests largely on case series and physiological reasoning.
The technical endpoint is visible separation of the nerve from the intended adjacent surfaces, without intraneural spread.
In practice hydrodissection is best understood as an adjunct within a wider plan rather than a definitive treatment, and it is not currently part of the established UK carpal tunnel pathway, in which night splinting, activity modification, corticosteroid injection and referral for surgical decompression remain the standard options. Where it is used it is an additional option for mild to moderate symptoms or for patients who wish to avoid or delay surgery. Severe disease with constant numbness, thenar wasting or significant denervation warrants prompt referral for surgical assessment, and hydrodissection should not be used to postpone that, which is the most important clinical judgement on this page. The procedure is safe in trained hands, with the principal risks being intraneural injection, vascular puncture and the general risks of any injection, and it should be performed only by clinicians competent in nerve ultrasound. Where it is offered, the patient should be told that the evidence is promising but limited, particularly outside the carpal tunnel.
Exam Tips
•Nerve hydrodissection uses ultrasound-guided fluid injection to separate a nerve mechanically from adherent surrounding tissue, producing a visible fluid halo.
•The technical endpoint is visible separation of the nerve from the intended adjacent surfaces without intraneural spread; injection stops if there is sharp radiating pain or fascicular swelling, but their absence does not exclude intraneural placement, particularly after local anaesthetic.
•In the carpal tunnel a commonly used approach is in-plane from the ulnar side, separating the median nerve from the flexor retinaculum above and the flexor tendons below, with the ulnar artery and nerve positively identified on ultrasound and colour Doppler.
•Injectates include normal saline, five per cent dextrose in water, local anaesthetic and corticosteroid; dextrose has encouraging comparative data in carpal tunnel syndrome, limited by small heterogeneous trials.
•Evidence is strongest in carpal tunnel syndrome and much weaker at other sites, where it rests largely on case series.
•Hydrodissection is not part of the established UK carpal tunnel pathway; severe disease with constant numbness, thenar wasting or significant denervation warrants prompt referral for surgical assessment and must not be delayed by it.